Garland J. Scott 4

What Happened Garland J. Scott, a director of Olema Pharmaceuticals, was granted a derivative award (stock option) for 29,500 shares on June 18, 2026. The Form 4 reports the acquisition as 29,500 shares at $0.00 (derivative), so no cash changed hands at grant. This is a compensation grant (acquisition), not a sale or open-market purchase.

Key Details

• Transaction date: 2026-06-18; Form 4 filed: 2026-06-23 (Form 4s are typically due within two business days — this filing appears to be one business day late).
• Transaction type: Grant / award of a derivative instrument (option) covering 29,500 shares; reported price $0.00; reported value $0.
• Shares owned after transaction: Not specified in the provided filing.
• Vesting (footnote F1): shares subject to the option vest in 12 equal monthly installments beginning June 18, 2026, subject to continuous service; if not fully vested, the option vests in full on the issuer’s next annual meeting date, subject to continued service.
• No indication in the filing of a 10b5-1 plan, tax withholding, or an immediate sale of shares.

Context This was an equity compensation grant to a director — a routine, non-cash award that creates a future right to shares if vesting conditions are met. Such grants do not reflect an immediate buy or sell by the insider; watch future Form 4s for exercises or sales that convert these options into stock or cash.